Screening for diabetes prevention with diabetes risk scores - A balancing act
| dc.contributor.author | Lee, Crystal | |
| dc.contributor.author | Versace, Vincent L | |
| dc.contributor.author | Malo, Jonathan A | |
| dc.contributor.author | Shaw, Jonathan | |
| dc.contributor.author | Dunbar, James | |
| dc.contributor.author | Colagiuri, Stephen | |
| dc.date.accessioned | 2019-04-29T01:41:24Z | |
| dc.date.issued | 2018-01 | |
| dc.date.updated | 2019-03-12T07:34:56Z | |
| dc.description.abstract | Aims: To compare the diabetes prevention impact and cost of several screening scenarios for diabetes prevention programs with the scenario which included an oral glucose tolerance test (OGTT). Methods: We included 4864 participants of the Australian Diabetes, Obesity and Lifestyle study who were aged ≥40 years, did not have known diabetes at baseline, and attended the five year follow-up. The proportions of participants eligible or ineligible for diabetes prevention program were estimated for each scenario. The costs of screening and diabetes prevention programs were also estimated. Results: Screening with OGTT alone identified 21% of participants as eligible for diabetes prevention. While 3.1% of the cohort were identified as high risk and developed diabetes after five years, 1.0% of the cohort were identified as low risk and developed diabetes. The population prevention potential (i.e. sensitivity) for OGTT alone was 76.5%. Screening all Australian adults aged ≥40 years in 2015 by OGTT would have cost a total of AU$2025 million (AU$1031 million on screening and AU$994 million on prevention programs). The total costs of screening and prevention were substantially lower when AUSDRISK was used alone or in combination with a blood test. However, the population prevention potentials were also lower (ranged from 20.1% to 50.7%). Conclusions: A blood test post non-invasive risk assessment is a worthwhile step in the process of enrolling participants in a diabetes prevention program. Nevertheless, there will be ineligible individuals who proceed to diabetes. | en_AU |
| dc.description.sponsorship | The AusDiab study co-coordinated by the Baker Heart and Diabetes Institute, gratefully acknowledges the generous support given by: National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing. Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Bristol-Myers Squibb, City Health CentreDiabetes Service-Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services – Tasmania, Department of Health – New South Wales, Department of Health – Western Australia, Department of Health – South Australia, Department of Human Services – Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, Sanofi Synthelabo and the Victorian Government’s OIS Program. | en_AU |
| dc.format.extent | 8 pages | en_AU |
| dc.format.mimetype | application/pdf | en_AU |
| dc.identifier.issn | 0168-8227 | en_AU |
| dc.identifier.uri | http://hdl.handle.net/1885/160681 | |
| dc.language.iso | en_AU | en_AU |
| dc.publisher | Elsevier BV | en_AU |
| dc.relation | http://purl.org/au-research/grants/nhmrc/233200 | en_AU |
| dc.source | Diabetes Research and Clinical Practice | en_AU |
| dc.subject | Screening | en_AU |
| dc.subject | Diabetes prevention | en_AU |
| dc.subject | Risk assessment | en_AU |
| dc.title | Screening for diabetes prevention with diabetes risk scores - A balancing act | en_AU |
| dc.type | Journal article | en_AU |
| dcterms.dateAccepted | 2017-11-10 | |
| local.bibliographicCitation.lastpage | 127 | en_AU |
| local.bibliographicCitation.startpage | 120 | en_AU |
| local.contributor.affiliation | Lee, Crystal, University of Sydney | en_AU |
| local.contributor.affiliation | Versace, Vincent L, Deakin University | en_AU |
| local.contributor.affiliation | Malo, Jonathan, College of Health and Medicine, The Australian National University | en_AU |
| local.contributor.affiliation | Shaw, Jonathan, Baker IDI Heart and Diabetes Institute | en_AU |
| local.contributor.affiliation | Dunbar, James, Deakin University | en_AU |
| local.contributor.affiliation | Colagiuri, Stephen, University of Sydney | en_AU |
| local.contributor.authoruid | Malo, Jonathan, u5939590 | en_AU |
| local.description.embargo | 2037-12-31 | |
| local.description.notes | Imported from ARIES | en_AU |
| local.identifier.absfor | 110306 - Endocrinology | en_AU |
| local.identifier.absfor | 111104 - Public Nutrition Intervention | en_AU |
| local.identifier.absseo | 920104 - Diabetes | en_AU |
| local.identifier.ariespublication | u4485658xPUB2510 | en_AU |
| local.identifier.citationvolume | 135 | en_AU |
| local.identifier.doi | 10.1016/j.diabres.2017.11.009 | en_AU |
| local.identifier.scopusID | 2-s2.0-85036581789 | |
| local.identifier.thomsonID | 000423832500019 | |
| local.publisher.url | https://www.elsevier.com/en-au | en_AU |
| local.type.status | Published Version | en_AU |
Downloads
Original bundle
1 - 1 of 1
Loading...
- Name:
- 01_Lee_Screening_for_diabetes_2018.pdf
- Size:
- 602.59 KB
- Format:
- Adobe Portable Document Format